drugset / Trial / NCT00943592
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.
Timeline
- Start
- 2006-03
- Primary completion
- 2011-04
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 20 mg | — |
| Subject | Clofarabine | Other / unclassified | — | Intravenous |
| Subject | Melphalan | Small molecule | 100 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |